Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s pipeline consists of two compounds: seclidemstat (SP-2577), a small molecular inhibitor and SP-3164, a small molecular protein degrader. SP-2577 is a small-molecule lysine specific demethylase 1 (LSD1) inhibitor with a scaffold. LSD1 is an enzyme that is, in part, responsible for epigenetic regulation of genes that support cancer growth. SP-3164 is a cereblon binding molecular glue. SP-3164 degrades transcription factors IKZF1 and IKZF3, along with other proteins, resulting in both direct anti-cancer activity and immune-modulating properties. SP-3164 has activity in both hematologic and solid tumors. The SLRX average annual return since 2015 is shown above.
The Average Annual Return on the SLRX average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SLRX average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SLRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free SLRX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
